Single-cell RNA sequencing reveals novel and highly diverse transcriptomic patterns 34 characteristic of CD4 + T cell responses to tumors. 35
Immune responses have the potential to restrain cancer development, and most 52 immunotherapy strategies aim to reinvigorate T cell function to unleash effective anti-tumor 53 immune responses (1-5). Cytotoxic CD8 + T lymphocytes are being exploited in clinical settings 54 due to their ability to recognize tumor neo-antigens and kill cancer cells (3, 6). However, 55 effective anti-tumor immunity relies on a complex interplay between diverse lymphocyte subsets 56 that remain poorly characterized. CD4 + T helper cells, which are essential for effective immune 57 responses and control the balance between inflammation and immunosuppression (4, 7-9), have 58 recently emerged as potential therapeutic targets (4-6, 10-14). CD4 + helper cells contribute to the 59 priming of CD8 + T cells and to B cell functions in lymphoid organs (4, 15, 16) . CD4 + T helper 60 type-1 (Th1) cells secrete the cytokine IFN-g and affect tumor growth by targeting the tumor 61 microenvironment (TME), antigen presentation through MHC class I and II, and other immune 62 cells (17-22). Conversely, Th2 cells can promote tumor progression and regulatory T cells (Treg) 63 mediate immune tolerance, suppressing the function of other immune cells and thus preventing 64 ongoing anti-tumor immunity (23) (24) (25) . 65
Despite the anti-tumor potential of CD4 + T cells, disentangling their functional diversity 66 has been the limiting factor for pre-clinical and clinical progress. While several studies have 67 assessed the transcriptome of Treg cells or their tumor reactivity (25 , 26-31) , the functional 68 diversity of conventional (non-Treg) tumor-infiltrating lymphocytes (TILs) has remained poorly 69 understood. Population studies have limited power at identifying new, and especially rare 70 functional cell states. Conventional single-cell approaches (e.g. flow or mass cytometry) 71 overcome this obstacle but are necessarily restricted to hypothesis-based targets because of the 72 number of parameters they can analyze. Furthermore, most previous studies, whether of human 73 or in experimental tumors, did not distinguish tumor antigen-specific from bystander CD4 + T 74 cells, even though bystanders may form the vast majority of conventional (non-Treg) T cells in 75 the TME (28, (30) (31) (32) (33) (34) (35) , in particular in draining lymphoid organs, where immune responses are 76 typically initiated. 77
To address these challenges, we applied the resolution of single-cell RNA-sequencing 78 (scRNAseq) to a tractable experimental system assessing tumor-specific responses both in the 79 tumor and in lymphoid organs, and we designed new computational analyses to identify 80 transcriptomic similarities. Our analyses dissect the complexity of the CD4 + T cell response to 81 tumor antigens and identify broad transcriptomic divergences between anti-tumor and anti-viral 82 responses. Emphasizing the power of this approach, new transcriptomic patterns identified in the 83 present study are also found in CD4 + T cells infiltrating human tumors and correlate with 84 response to checkpoint therapy in human melanoma. 85
Results and Discussion 86
Tracking tumor-specific CD4 + 
T cells 87
We set up a tractable experimental system to study tumor antigen-specific CD4 + T cells. 88
We retrovirally expressed the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) in 89 colon adenocarcinoma MC38 cells, using a vector expressing mouse Thy1.1 as a reporter 90 ( Figure S1A) . Subcutaneous injection of the resulting MC38-GP cells produced tumors allowing 91 analysis of immune responses by day 15 after injection. We tracked GP-specific CD4 + T cells 92 through their binding of tetramerized I-A b MHC-II molecules associated with the GP-derived 93 GP66 peptide (36). Such CD4 + cells were found in the tumor and draining lymph node (dLN) of 94 MC38-GP tumor bearing mice, but neither in non-draining LN (nLN) from MC38-GP mice, nor 95 in mice carrying control MC38 tumors ( Figure S1B) . 96
To study the CD4 + T cell response to tumor antigens, we aimed to produce genome-wide 97 single cell mRNA expression profiles (scRNAseq) in CD4 + TILs and CD4 + dLN cells. We sorted 98 GP66-specific T cells from dLNs, as these were the only dLN CD4 + T cells for which tumor 99 specificity could be ascertained. Among TILs, we noted that ~87% of GP66-specific CD4 + T 100 cells expressed Programmed Cell Death 1 (PD-1, encoded by Pdcd1, Figure S1C ), a marker of 101 persistent antigenic stimulation (37). Thus, to obtain a broad representation of antigen-specific 102
TILs, not limited to GP-specific cells, we used PD-1 expression as a surrogate for tumor antigen 103 specificity and purified tumor CD4 + CD44 hi PD-1 + T cells (PD-1 hi TIL) for scRNAseq. We 104 verified critical conclusions of the scRNAseq analyses by flow cytometry, comparing GP66-105 specific and PD-1 hi TILs. 106
Tumor-responsive CD4 + T cells are highly diverse 107
We captured GP66-specific dLN and PD-1 hi TIL (dLN and TILs hereafter, respectively) 108 CD4 + cells using the 10x Chromium scRNAseq technology (38); additionally, we captured 109 GP66-specific spleen CD4 + T cells from LCMV (Armstrong strain)-infected mice (36) as a 110 technical and biological reference (Figure S1D, called 'LCMV cells' here). We excluded cells of 111 low sequencing quality (low number of detected genes), potential doublets, and B cell 112 contaminants, leaving 566 dLN, 730 TIL, and 2163 LCMV CD4 + T cells for further analyses 113 (Table S1) . 114
We defined groups of cells sharing similar transcriptomic profiles using Phenograph 115 clustering (39). Consistent with previous studies (40), LCMV cells segregated into follicular 116 helper (Tfh, providing help to B cells) and type-1 helper (Th1, secreting the cytokine IFN-g) T 117 cells, among other subsets ( Figure S2A ). Tfh cells expressed Tcf7 (encoding the transcription 118 factor Tcf1), Cxcr5, and Bcl6, whereas Th1 cells expressed Tbx21 (encoding the transcription 119
factor T-bet), Ifng (IFN-g), and Cxcr6. Low resolution clustering identified 5 groups of TILs and 120 dLN cells ( Figure S2B) . Groups I and II had features of Th1 cells, although group II differed by 121 higher expression of the chemokine receptor Cxcr3 and lower expression of Ifng. Group III 122 expressed genes typical of Treg cells, including Foxp3 and Il2ra, encoding CD25 (IL-2Ra). 123
Groups IV and V expressed Tfh cell genes, including Bcl6 and Cxcr5, and group IV Ccr7, which 124 preferentially marks memory cell precursors at the early phase of the immune response (40, 41) . 125
To further dissect these populations, we developed a user-independent, data-driven 126 approach to increase clustering resolution while controlling for false discovery. Applying such 127 high-resolution clustering separately to TILs and dLN cells, we identified 15 clusters (TIL 128 clusters t1-t7 and dLN clusters n1-n8), refining the original five main groups (Figure 1A) . 129
Revealing unexpected diversity among Th1-like TILs, group I and II resolved into 5 130 subpopulations, including a distinct cluster (t5) expressing higher levels of Il7r (encoding IL-131 7Ra) and lower levels of Tbx21 and Ifng. Only cluster group III (Tregs) included both TIL and 132 dLN cells, which expressed variable levels of Tbx21. Groups IV and V, the bulk of dLN cells, 133 resolved into 5 and 2 clusters, respectively. Consistent with flow cytometric analysis, dLN cells 134 neither expressed high levels of T-bet, the product of Tbx21, nor exhibited Th1 attributes; in 135 contrast, most TILs expressed T-bet, even if at various levels (Figure 1A and S2C, D) . 136
To support these observations, we analyzed pooled TILs and dLN cells by t-Distributed To verify the robustness of these observations, we analyzed a biological replicate 146 consisting of 1123 TILs and 675 dLN GP66-specific cells captured from a separate set of tumors 147
( Figure S2G and Table S1 ). Because batch-specific effects can confound co-clustering from 148 distinct experiments, we separately clustered cells from each replicate. To compare these 149 clusters, we evaluated the correlation between cluster-specific fold-change (FC) vectors, defined 150 internally to each replicate, that recorded expression of each gene in a cluster relative to all other 151 clusters in that replicate. We found significant inter-replicate matches for most clusters ( Figure  152 1D), supporting the reproducibility of the underlying transcriptomic patterns. Thus, scRNAseq 153 analysis of tumor-specific CD4 + T cells identifies an unsuspected diversity of transcriptomic 154 programs in the TME and dLN. 155
Correlation analyses mitigate tissue-context-specific factors 156
Comparison of TILs, dLN, and LCMV cells showed little overlap, including between 157
TILs and dLN cells (Figure S2H, left) . Thus, we considered that the impact of tissue of origin 158 could be the primary driver of clustering and mask commonalities in effector programs. Indeed, 159 most TIL subpopulations had attributes of tissue residency, including low S1pr1 and Klf2 160 expression, and high expression of Cd69, contrasting with LCMV and most tumor dLN clusters 161 ( Figure 1E ) (43). Only group III Tregs, and separately cells undergoing cell cycle, clustered 162 together regardless of origin (Figure S2H, right) . This prompted us to search for potential 163 underlying similarities among these disparate transcriptomic patterns. We found that data 164 integration approaches designed to uncover similarities across experimental conditions could not 165 overcome the separation resulting from biological context ( Figure S3A) , and could miss 166 functionally relevant differences (e.g. between Foxp3 + and Foxp3 -TILs, Figure S3B ) (44) . 167
Thus, we considered the correlation analysis used above for cluster matching. This analysis 168 distributed the 40 reproducible clusters (out of a total of 47 from all experiments) into 6 'meta-169 clusters' (with manual curation attaching meta-cluster 1 b to 1 a ), of which four (meta-clusters 1, 170 3, 5 and 6) comprised cells of more than one tissue context (Figure 2A and Table S2 ). Thus, the 171 correlation analysis establishes relatedness among transcriptomic patterns identified by 172 conventional clustering. 173
Characterizing transcriptomic similarities 174
We further characterized the meta-clusters by identifying their defining overexpressed 175 genes. In addition to Foxp3 and Il2ra, genes driving meta-cluster 3 (Treg, group III) included Contrasting with Treg clusters, the correlation analysis failed to detect similarities between 182 the three groups of T-bet-expressing cells. These cells, which showed heterogeneous Tbx21 183 levels, were distributed into meta-clusters 2 (TILs group II, t3-4), 4 (LCMV cells) and 6 (TILs 184 group I, t1-2) (Figure 2A) . The two TIL meta-clusters showed multiple differences from 185 in tumors with micro-satellite instability, suggesting specificity for tumor antigens. The mouse 199
LCMV-responsive Th1 cells, including higher expression of
Th1 TILs identified in our study had higher expression of 40 genes from the human colon TIL 200 Th1 signature, including Bhlhe40 and Lag3 (Table S3) , with a significant (p=0.001) skewing 201 towards this signature detected by GSEA (48). However, mouse Th1 TILs lacked expression of 202 other components of the human signature, including Gzmb and Irf7, suggesting that the impact of 203
Bhlhe40 expression on TIL transcriptomes is in part context-specific. 204
Meta-cluster 6 unexpectedly associated Th1 TILs and a dLN Ccr7 + cluster (Group IV 205 cluster n5) (Figure 2A) , suggesting a potential link between TILs and dLN. The association was 206 driven by transcriptional regulators Bhlhe40 and Id2, and TNF superfamily members Tnfsf8 207 (encoding CD30L) and Tnfsf11 (RANKL) (Figures 3A and 1E) . The potential connection 208 between Ccr7 + dLN cells and Th1 TILs was specific to Ccr7 + cluster n5, which segregated from 209 n6 and other dLN subsets (Tfh and Treg) based on higher expression of Ifng (but not Tbx21) and Table S3 and Figure 1E ). This includes expression of Tcf7, a 214 transcription factor important to prevent T cell terminal differentiation and for CD8 + T cells 215 responsiveness to PD-1 blockade (49-56). However, the correspondence between MC38-GP dLN 216
Ccr7 + clusters and the LCMV Tcmp signature was only partial (Table S3) . 217
Meta-cluster 1 comprised LCMV Tfh clusters and dLN group V Tfh clusters (Figure 2A) . 218
We verified that the abundance of dLN Tfh cells was similar in mice carrying MC38-GP and 219 MC38 tumors (Figure S3G) , indicating that this response is not a consequence of GP expression. 220 (Figure 3E, 1E and S3H) . Unexpectedly, 223 meta-cluster 1 associated the dLN and LCMV Tfh clusters with TIL group II cluster t5, 224 characterized by Il7r expression (Figures 2A and 1A) , based in part on intermediate expression 225
of Tcf7 (1.6 fold relative to other TIL subpopulations) (Figure 3F and 1E) . Flow cytometric 226 analysis confirmed the abundance of GP66-specific IL-7R + TILs (Figure 3G ). In addition, the 227 Tcf7 int t5 cluster showed expression of the transcription factor Klf2 and its downstream target 228
Sphingosine-1-phosphate receptor 1 (S1pr1). This indicated retention of a cell trafficking 229 transcriptional program (57) (Figure 3F and 1E) and contrasted with the interferon-driven Isc 230
TILs. Thus, we designated cluster t5 of group II TILs as putative non-resident cells (nRes 231 hereafter). 232
To further delineate the relationships between cell clusters, we used Reversed Graph 233
Embedding (58), which has been used to estimate progression through transcriptomic states. This 234 placed the dLN Tfh and TIL Th1 and Isc at the end of an inferred path (Figure 3H) , nRes TILs 235 in the middle of the continuum and Ccr7 + dLN cells between Tfh and nRes. These analyses, 236 combined with the similarities described by meta-clustering, support the notion that the tumor-237 responsive CD4 + T cell response may be characterized as a transcriptomic continuum; they 238 confirm the transcriptomic distance between Th1 and Isc TILs, even though both subsets express 239 T-bet, the Th1-defining factor. 240
TILs subpopulation-specific dysfunction gene programs 241
We reasoned that expression of a dysfunction-exhaustion program (59, 60) may account 242 for the limited relatedness between LCMV and TIL Th1 cells, as TILs expressed multiple 243 exhaustion marks (Figure 4A) , and were sorted for PD-1 expression for scRNAseq. To assess 244 the impact of exhaustion on TIL subpopulation, we defined TIL Th1, Isc, nRes and Treg gene 245 signatures as the genes preferentially expressed in each subpopulation relative to all other TILs 246 (Table S4) . We found a significant overlap between multiple viral-response exhaustion gene 247 signatures (MSigDB) (61) and the Th1 and Treg signatures ( Table S5 ). Separate analysis of a 248 previously reported gene signature characterizing CD4 + T cell dysfunction during chronic 249 infection (62) indicated a significant overlap with the Isc signature, but not with Th1 and Treg 250 signatures ( Figure S4A , Table S6 ). 251
The latter result suggested heterogeneous expression of exhaustion genes among TIL 252 subsets. We tested this possibility using a broader set of exhaustion genes shared across cancer 253 and chronic infection (63). 55 genes from this set were also part of TIL Th1, Isc, or Treg 254 signatures. However, their overlap was heterogeneous, identifying dysfunction programs specific 255 of TIL subpopulations (Figure 4B , Table S6 ). Of note, we did not detect overlap between any 256 dysfunction-exhaustion signature and nRes TILs (Figure 4B, Table S6 ). This is in line with 257 these cells' residual expression of Tcf7, which in CD8 + T cells marks cells with conserved 258 responsiveness (52-54, 64). 259
The Isc IFN signature correlates with poor clinical prognosis in human tumors 260
Last, we examined if MC38-GP TIL transcriptomic patterns were observed in human 261 tumors. We analyzed published CD4 + Human liver cancer TILs (TILHLC) scRNAseq data pooled 262 across six treatment-naive patients (28). High resolution clustering separated the TILHLC cells 263 into 11 clusters, which could be combined into groups displaying features of Th1, Isc, Treg TILs 264 and cells undergoing cell cycle (Figure 4C) . While pooled analysis of CD4 + PD-1 + TILs from 265 MC38-GP tumors (TIL) with TILHLC only identified similarities between cells undergoing cell 266 cycle (Figure S4B and S4C) , cluster correlation analysis indicated significant similarities 267 between Tregs, cell cycle, and Isc clusters from TIL vs. TILHLC (Figure 4D, top) . We focused on 268 the Isc pattern, which differed the most from previously reported Th1 and Treg transcriptomic 269 profiles. We found a significant overlap of overexpression patterns between TIL Isc and their 270 human counterpart, including type I IFN-induced genes and Irf7 (65) (Figure 4D, bottom and 271   Table S7 ). Thus, the Isc signature newly identified among mouse CD4 + TILs is found in human 272
tumors. 273
These finding were not unique to liver tumors, as analysis of CD4 + CD3 + human melanoma 274
TILs across 48 lesions (TILMel) (33) identified a cluster enriched in Isc characteristic genes, 275 among other populations (Figure S4D) . To investigate the relationships between Isc 276 transcriptomic program and clinical prognosis, we evaluated the association between the 277 expression in TILMel of Isc signature genes (defined in MC38-GP TILs) and patient response to 278 checkpoint therapy. Relative to responders, non-responsive tumors had significantly higher 279 fractions of cells expressing Isc signature genes (49 out of 108 genes, adjusted p-value < 0.05), 280
including Stat1, Irf7 and Irf9 (Figure 4E and Table S8 ). This indicated negative association 281 between the Isc transcriptomic program and patient response to checkpoint therapy. Thus, the 282 methods used in the present study identify transcriptomic programs shared by multiple tumor 283 types and of potential prognostic significance. 284
In summary, using scRNAseq and data-driven computational approaches, the present study In conclusion, this study provides a high-resolution characterization of tumor-reactive 315 CD4 + T cell responses in lymphoid organs and the tumor microenvironment. We identify 316 previously unrecognized transcriptomic patterns among tumor-specific T cells and provide an 317 extensive mapping of the CD4 + T cell immune response against cancer. We describe new 318 analytical approaches of broad applicability, including to clinical data, that combine high 319 resolution dissection of transcriptomic patterns and synthetic data integration to identify 320 correspondences between apparently unrelated cell differentiation states. 321
Materials and Methods 322 323
Mice. C57BL/6 mice were purchased from the National Cancer Institute Animal 324
Production Facility and were housed in specific pathogen-free facilities. Animal procedures were 325 approved by the NCI Animal Care and Use Committee. sequenced on multiple runs of Illumina NextSeq using paired-end 26x98bp or 26x57bp to reach 368 a sequencing saturation greater than 70% resulting in at least 49000 reads/cell. 369 scRNA-seq data pre-processing. De-multiplexing, alignment to the mm10 transcriptome 370 and unique molecular identifier (UMI) calculation were performed using the 10X Genomics 371
Cellranger toolkit (v2.0.1, http://software.10xgenomics.com/single-cell/overview/welcome). Pre-372 processing, dimensionality reduction and clustering analyses procedures were applied to each 373 dataset (that is, specific tissue origin in each experiment) independently to account for dataset-374 specific technical variation such as sequencing depth and biological variation in population 375 composition, as follows. We filtered out low quality cells with fewer than 500 detected genes 376
(those with at least one mapped read in the cell). Potential doublets were defined as cells with 377 number of detected genes or number of UMIs above the 98 th quantile (top 2% owing to up to 2% 378 estimated doublets rate in the 10X Chromium system). Potentially senescent cells (more than 379
10% of the reads in the cell mapped to 13 mitochondrial genes) were also excluded. Library size 380 ( # , number of UMIs in cell j) normalization and natural log transformation were applied to 381 each cell library, i.e., where # ( is the number of reads for gene i in cell j. 383 Dimensionality reduction. Highly variable genes were defined as genes with greater than 384 one standard deviation of the dispersion from the average expression of each gene. However, to 385 account for heteroscedasticity, variable genes were identified separately in bins defined based on 386 average expression. PCA analysis was performed on the normalized expression of the set of 387 dataset-specific highly variable genes. We selected the top PCs based on gene permutation test 388 (74). 'Barnes-hut' approximate version of t-SNE (75) (perplexity set to 30, 10k iterations) was 389 applied on the top PCs to obtain a 2D projection of the data for visualization. 390
Gene signature activation quantification. Gene signature activation was quantified 391 relative to a technically similar background gene set as described in (76). Briefly, we identify the 392 top 10 most similar (nearest neighbours) genes in terms of average expression and variance, then 393 define the signature activation as the average expression of the signature genes minus the 394 average expression of the background genes. GP66 tetramer staining signature definition is 395 described in Supplementary Note. Additionally, we defined lists of ribosomal, mitochondrial, 396 and cell cycle genes (77) for confounder controls (Table S10) . LCMV cells showed little overlap even after correcting for potential confounders. 416
After obtaining the initial clusters and identifying the overexpressed genes in each cluster, 417 we apply two filters: (1) we exclude small clusters of B cells (CD79 + populations) from each 418 dataset.
(2) We identify PCs driven by B cell marker genes and remove the individual cells 419 whose expression profile has high scores for those PCs (outliers). We then repeat the entire 420 processing and clustering to prevent detecting highly variable genes and PCs driven by 421 contaminations, which may in turn reduce the signal of other small populations of interest. 422
Differential expression analysis and population matching. Differential expression was 423 performed using Limma (version 3.32.10). We initially performed differential expression 424 analysis between each cluster against the pool of all other clusters within a given dataset. 425
Identified clusters were labelled as a known T cell subtype if the majority of the known subtype-426 defining genes were differentially over-expressed in that cluster. We then matched populations 427 across experiments to assess the reproducibility of the populations and to uncover similarities 428 across datasets that are masked due to overall tissue-context-specific differences. To reduce the 429 effects of tissue-context-specific effects on the similarity calculation, we used the fold change 430 relative to all other clusters (background) of the same dataset). Then we measured the Pearson 432 correlation between the FC vectors of all pairs of clusters across datasets. We compare this 433 approach with an alternative approach that uses Euclidean distances between the average 434 expression vectors, defined as average expression of all genes in a cluster and a recent data 435 integration approach (44) following tutorial specifications 436 Robust cluster calling and robust population comparisons. For each dataset, we defined 438 'robust clusters' as those that had highly similar match in the biological replicate. High similarity 439 is defined as Pearson correlation coefficient greater than ~1.28 standard deviations from the 440 mean for each dataset, corresponding to nominal p-value of 0.1. Hierarchical clustering was 441 performed on the identified robust clusters using the inter-cluster similarity matrix, where the 442 similarity was defined as above using the Pearson correlation between the FC vectors. Using the 443 vector of average expression vectors did not achieve similar result; specifically, using 444 hierarchical clustering of the Euclidean distances between the clusters average expression vector 445 retained the grouping of clusters based on origin tissue (Figure S3A) . We then analyzed 446 differential expression patterns for clusters belonging to each meta-cluster, excluding cell cycle 447 clusters. For a given pair of clusters of interest, A and B in datasets X and Y respectively, we 448 performed three differential expression analyses: (1) differential expression in A relative to other 449 clusters in X, (2) differential expression in B relative to other clusters in Y, and (3) differential 450 expression in A relative to B. In addition to average expression differences, we quantified the 451 detection rate of gene X as proportion of cells where 1 or more reads was mapped to X and 452 prioritized differentially expressed genes exhibiting also differential detection across conditions. 453
This analysis was performed for the two replicates separately and the results interpreted jointly; a 454 gene was deemed as over-expressed in cluster A in tissue X if it is over-expressed relative to 455 other clusters in X as well as relative to B, in both replicates. 456 scRNAseq contour plots. Normalized scRNAseq expression measurements were 457 visualized as contours, where zero (0) values were assigned random value drawn from a normal 458 distribution centered around 0. 459
Reversed Graph Embedding. Trajectory analysis of TIL populations (group I and II, 460
excluding group III Tregs) was performed using Monocle (version 2.9.0, parameters 461 max_components = 2, method = DDRTree). 462 Gene signature definition. For each TIL subpopulation (group I Th1, group II Isc, group 463 II nRes and group III Treg) we selected overexpressed genes exhibiting differential detection (as 464 defined above) relative to all other TILs across both experiments (Table S4) . 465
Correspondence to human data. Human liver cancer TIL scRNAseq counts were 466 downloaded from GEO [GSE98638]. Non-CD4 + T cells were filtered based on the classification 467 in the original publication (28). Human gene symbols were translated to Mouse gene symbols 468 using package biomaRt (version 2.37.8). Pre-processing, clustering and population matching 469 analysis were applied as described above. Human melanoma TILs data scRNAseq counts were 470 downloaded from GEO [GSE120575]. We selected CD4 + T cells as cells with at least one 471 mapped read to CD4 and [CD3D or CD3E or CD3G], following the authors definition (33). 108 472 out of 136 Isc signature genes were mapped to human gene symbols. The detection rate of each 473
Isc signature gene (as defined above) in each lesion were used to assess differential detection 474 across responders and non-responders. We used two-sided Wilcoxon test to quantify the 475 significance of differential activation. vectors (as defined in text) (left) annotated with cluster origin and cluster group or type (right).
799
(B) Bar plot shows relative cluster composition of Foxp3 + or Foxp3 -TILs and Foxp3 -LCMV (no 800
Foxp3 + cells found in GP66 + LCMV) after applying a data integration approach (44). (C) 801
Heatmap shows row-standardized expression of TIL Isc and Th1 characteristic genes across TIL, 802 dLN and LCMV clusters. 
